The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 12, 2016

Filed:

Sep. 26, 2013
Applicant:

Miami University, Oxford, OH (US);

Inventor:

Michael A. Kennedy, Oxford, OH (US);

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); C07H 21/04 (2006.01); A61K 31/70 (2006.01); A61K 31/7068 (2006.01); C12N 15/115 (2010.01); A61K 31/7088 (2006.01); A61K 31/7125 (2006.01); A61K 31/713 (2006.01); C12Q 1/68 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7068 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 31/7125 (2013.01); C12N 15/115 (2013.01); C12N 2310/16 (2013.01); C12N 2310/315 (2013.01);
Abstract

Elevated high mobility group A (HMGA) protein expression in human cancer cells, and especially human pancreatic cancer cells, is correlated with resistance to the chemotherapy agent gemcitabine. The present invention uses HMGA-targeted AT-rich phosphorothioate DNA (AT-sDNA) aptamers to suppress HMGA carcinogenic activity. Cell growth of human pancreatic cancer cells (AsPC-1 and Miapaca-2) transfected with AT-sDNA were monitored after treatment with gemcitabine. Significant increases in cell death in AT-sDNA transfected cells compared to non AT-rich sDNA treated cells were observed in both cell lines. The data indicates the potential use of HMGA targeted DNA aptamers to enhance chemotherapy efficacy in human cancer treatment, and in particular human pancreatic cancer treatment.


Find Patent Forward Citations

Loading…